XNCR
Xencor Inc
NASDAQ · Healthcare · Biotechnology · US
$23.19
+1.49%Oct 19, 2026, 11:01 UTC
Xencor announced that it will host a webcast on October 26 to discuss Phase 1 study results for XmAb819 in advanced clear cell renal cell carcinoma.
Source:Aug 5, 2026, 00:00 UTC
Xencor Inc reported Q2 2026 total revenue of $51.2 million, a 17.4% increase year-over-year, with a net loss of $21.7 million and diluted EPS of -$0.29.
Source: